Your browser doesn't support javascript.
loading
Endoscopic ultrasound-guided intraportal injection of autologous bone marrow in patients with decompensated liver cirrhosis: A case series.
Zheng, Shao-Peng; Deng, Ao-Jian; Zhou, Jing-Jing; Yuan, Ling-Zhi; Shi, Xiao; Wang, Fen.
Afiliación
  • Zheng SP; Department of Gastroenterology, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
  • Deng AJ; Hunan Key Laboratory of Non-resolving Inflammation and Cancer, Central South University, Changsha 410000, Hunan Province, China.
  • Zhou JJ; Department of Gastroenterology, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
  • Yuan LZ; Hunan Key Laboratory of Non-resolving Inflammation and Cancer, Central South University, Changsha 410000, Hunan Province, China.
  • Shi X; Department of Gastroenterology, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
  • Wang F; Department of Gastroenterology, Third Xiangya Hospital of Central South University, Changsha 410013, Hunan Province, China.
World J Gastrointest Surg ; 15(4): 655-663, 2023 Apr 27.
Article en En | MEDLINE | ID: mdl-37206071
BACKGROUND: Recently, stem cell therapy has been extensively studied as a promising treatment for decompensated liver cirrhosis (DLC). Technological advances in endoscopic ultrasonography (EUS) have facilitated EUS-guided portal vein (PV) access, through which stem cells can be precisely infused. AIM: To investigate the feasibility and safety of fresh autologous bone marrow injection into the PV under EUS guidance in patients with DLC. METHODS: Five patients with DLC were enrolled in this study after they provided written informed consent. EUS-guided intraportal bone marrow injection with a 22G FNA needle was performed using a transgastric, transhepatic approach. Several parameters were assessed before and after the procedure for a follow-up period of 12 mo. RESULTS: Four males and one female with a mean age of 51 years old participated in this study. All patients had hepatitis B virus-related DLC. EUS-guided intraportal bone marrow injection was performed in all patients successfully without any complications such as hemorrhage. The clinical outcomes of the patients revealed improvements in clinical symptoms, serum albumin, ascites, and Child-Pugh scores throughout the 12-mo follow-up. CONCLUSION: The use of EUS-guided fine needle injection for intraportal delivery of bone marrow was feasible and safe and appeared effective in patients with DLC. This treatment may thus be a safe, effective, non-radioactive, and minimally invasive treatment for DLC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: World J Gastrointest Surg Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: World J Gastrointest Surg Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos